Long-term safety study of HB0034 for GPP
Treatments studied
Part of Skin clinical trials.
This trial is for people who have already taken part in an earlier study of the drug HB0034 for generalized pustular psoriasis (GPP). It checks how safe and effective the drug is over a longer period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier HB0034-04 study for GPP and finished at least 12 weeks of it.
- Your doctor must agree that long-term treatment for GPP is right for you.
- If you or your partner could become pregnant, you must agree to use reliable birth control during the study and for 6 months after the last dose.
- You must be willing to follow the study plan and come to all follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry tracks the safety and effectiveness of GPP treatments in real-world settings. It helps doctors and researchers learn how well current and future medicines work for people with generalized pustular psoriasis.
This study tests an experimental drug called HB0034 for people with a sudden, severe flare of generalized pustular psoriasis (GPP). It aims to see if the drug can safely clear the pustules and improve symptoms.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This study tests how the body processes the experimental drug HPP737 in healthy Chinese men. It helps researchers understand how the drug is absorbed, broken down, and eliminated.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
Hear when a new Generalized Pustular Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.